ClinicalTrials.gg
Sign In

Neoplasms by Site clinical trials

The registry lists 208 studies for Neoplasms by Site across more than 10 countries. 53 are recruiting or about to start. 7 of them are mainly about Neoplasms by Site (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Neoplasms by Site studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
71
Recruiting
51
Terminated
33
Active, not recruiting
26
Status unknown
19
Withdrawn
4

Phase

Phase 2
83
Phase 1
57
Phase 3
42
Phase 4
6
Early Phase 1
2

Where

United States
119
France
45
Spain
41
United Kingdom
41
Canada
37
Italy
33

Who runs them

AstraZeneca (10) · Cancer Research UK (7) · Revolution Medicines, Inc. (6) · Steba Biotech S.A. (6) · Exact Sciences Corporation (6) · Eli Lilly and Company (5) · Hoffmann-La Roche (4) · Blueprint Medicines Corporation (4)

What is being tested here

Drugs under test in Neoplasms by Site studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Atezolizumab233
Alectinib223
Dabrafenib222
Trametinib222
Entrectinib222
Vemurafenib222
Cobimetinib222
Capmatinib222
AZD9833133
Pembrolizumab122

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 7 open · Immune checkpoint inhibitors 6 open · SERDs (estrogen receptor degraders) 2 open · Angiogenesis inhibitors 1 open · Antimitotic agents 3

Coming up

18phase 3 studies under way
23studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 51 Neoplasms by Site studies recruiting now, 40 (78%) set no upper age limit and 6 (12%) stop at 75 or younger. 7 (14%) take children under 18. 6 (12%) are for women only and 4 (8%) for men only; 3 (6%) take healthy volunteers.

Recruiting studies that take each age, of 51
AgeWomenMen
106 (12%)6 (12%)
1841 (80%)41 (80%)
3042 (82%)42 (82%)
4044 (86%)43 (84%)
5046 (90%)44 (86%)
6545 (88%)44 (86%)
7544 (86%)43 (84%)
8540 (78%)41 (80%)

Across all 208 studies, recruiting or not: 9% stop at 75 or younger and 3% at 65; 9% take children; 13% are for women only and 10% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neoplasms by Site studies take

Of 23 phase 2 interventional studies under Neoplasms by Site, half reached primary completion within 45 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 245 mo30–57 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Results posted1

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 208. Browse all 208 → or search them.